Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

314 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer.
She QB, Gruvberger-Saal SK, Maurer M, Chen Y, Jumppanen M, Su T, Dendy M, Lau YK, Memeo L, Horlings HM, van de Vijver MJ, Isola J, Hibshoosh H, Rosen N, Parsons R, Saal LH. She QB, et al. Among authors: van de vijver mj. BMC Cancer. 2016 Aug 2;16:587. doi: 10.1186/s12885-016-2609-2. BMC Cancer. 2016. PMID: 27484095 Free PMC article.
Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy.
Hannemann J, Kristel P, van Tinteren H, Bontenbal M, van Hoesel QG, Smit WM, Nooij MA, Voest EE, van der Wall E, Hupperets P, de Vries EG, Rodenhuis S, van de Vijver MJ. Hannemann J, et al. Among authors: van hoesel qg, van der wall e, de vries eg, van de vijver mj, van tinteren h. Br J Cancer. 2006 Nov 20;95(10):1334-41. doi: 10.1038/sj.bjc.6603449. Epub 2006 Oct 31. Br J Cancer. 2006. PMID: 17088909 Free PMC article. Clinical Trial.
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.
Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, Beijersbergen RL, Mills GB, van de Vijver MJ, Bernards R. Berns K, et al. Among authors: van de vijver mj. Cancer Cell. 2007 Oct;12(4):395-402. doi: 10.1016/j.ccr.2007.08.030. Cancer Cell. 2007. PMID: 17936563 Free article. Clinical Trial.
SIRAC: Supervised Identification of Regions of Aberration in aCGH datasets.
Lai C, Horlings HM, van de Vijver MJ, van Beers EH, Nederlof PM, Wessels LF, Reinders MJ. Lai C, et al. Among authors: van de vijver mj, van beers eh. BMC Bioinformatics. 2007 Oct 30;8:422. doi: 10.1186/1471-2105-8-422. BMC Bioinformatics. 2007. PMID: 17971227 Free PMC article.
Molecular profiles of progesterone receptor loss in human breast tumors.
Creighton CJ, Kent Osborne C, van de Vijver MJ, Foekens JA, Klijn JG, Horlings HM, Nuyten D, Wang Y, Zhang Y, Chamness GC, Hilsenbeck SG, Lee AV, Schiff R. Creighton CJ, et al. Among authors: van de vijver mj. Breast Cancer Res Treat. 2009 Mar;114(2):287-99. doi: 10.1007/s10549-008-0017-2. Epub 2008 Apr 19. Breast Cancer Res Treat. 2009. PMID: 18425577 Free PMC article.
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.
Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y, Sahin A, Symmans WF, Pusztai L, Nolden LK, Horlings H, Berns K, Hung MC, van de Vijver MJ, Valero V, Gray JW, Bernards R, Mills GB, Hennessy BT. Stemke-Hale K, et al. Among authors: van de vijver mj. Cancer Res. 2008 Aug 1;68(15):6084-91. doi: 10.1158/0008-5472.CAN-07-6854. Cancer Res. 2008. PMID: 18676830 Free PMC article.
314 results